

**7. Referenzen**

1. Green, J. (1994) The physicochemical structure of bone: cellular and noncellular elements. *Miner Electrolyte Metab* 20, 7-15
2. Marcus, R. (1994) Osteoporosis. *Blackwell Scientific Publications Boston*, 202-226
3. Prallet, B., Male, P., Neff, L., and Baron, R. (1992) Identification of a functional mononuclear precursor of the osteoclast in chicken medullary bone marrow cultures. *J Bone Miner Res* 7, 405-414
4. Nijweide, P. J., Burger, E. H., and Feyen, J. H. (1986) Cells of bone: proliferation, differentiation, and hormonal regulation. *Physiol Rev* 66, 855-886
5. Amling, M., and Delling, G. (1996) [Cell biology of osteoclasts and molecular mechanisms of bone resorption]. *Pathologe* 17, 358-367
6. Aufmkolk, B., Hauschka, P. V., and Schwartz, E. R. (1985) Characterization of human bone cells in culture. *Calcif Tissue Int* 37, 228-235
7. Sigelkow, H., Benzler, K., Atkinson, M. J., and Hufner, M. (1998) The use of confluence stages does not decrease the overall variability in primary human osteoblasts but can give additional information on differentiation in vitro. *Exp Clin Endocrinol Diabetes* 106, 217-225
8. Wada, Y., Kataoka, H., Yokose, S., Ishizuya, T., Miyazono, K., Gao, Y. H., Shibasaki, Y., and Yamaguchi, A. (1998) Changes in osteoblast phenotype during differentiation of enzymatically isolated rat calvaria cells. *Bone* 22, 479-485
9. Battmann, A., Jundt, G., and Schulz, A. (1997) Endosteal human bone cells (EBC) show age-related activity in vitro. *Exp Clin Endocrinol Diabetes* 105, 98-102
10. Miller, S. C., Bowman, B. M., Smith, J. M., and Jee, W. S. (1980) Characterization of endosteal bone-lining cells from fatty marrow bone sites in adult beagles. *Anat Rec* 198, 163-173
11. Aarden, E. M., Burger, E. H., and Nijweide, P. J. (1994) Function of osteocytes in bone. *J Cell Biochem* 55, 287-299
12. Gomez, B., Jr., Ardakani, S., Ju, J., Jenkins, D., Cerelli, M. J., Daniloff, G. Y., and Kung, V. T. (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. *Clin Chem* 41, 1560-1566
13. Malaval, L., Modrowski, D., Gupta, A. K., and Aubin, J. E. (1994) Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. *J Cell Physiol* 158, 555-572
14. Migliaccio, S., Davis, V. L., Gibson, M. K., Gray, T. K., and Korach, K. S. (1992) Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. *Endocrinology* 130, 2617-2624
15. Pfeilschifter, J., Diel, I., Pilz, U., Brunotte, K., Naumann, A., and Ziegler, R. (1993) Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. *J Bone Miner Res* 8, 707-717
16. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., and Higashio, K. (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. *J Biol Chem* 273, 5117-5123
17. Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., and Higashio, K. (1999) Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. *Biochem Biophys Res Commun* 265, 158-163
18. Jilka, R. L., Takahashi, K., Munshi, M., Williams, D. C., Roberson, P. K., and Manolagas, S. C. (1998) Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. *J Clin Invest* 101, 1942-1950
19. Lutton, J. D., Moonga, B. S., and Dempster, D. W. (1996) Osteoclast demise in the rat: physiological versus degenerative cell death. *Exp Physiol* 81, 251-260
20. Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M., and Manolagas, S. C. (1998) Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. *J Bone Miner Res* 13, 793-802
21. Takeda, S., Yoshizawa, T., Nagai, Y., Yamato, H., Fukumoto, S., Sekine, K., Kato, S., Matsumoto, T., and Fujita, T. (1999) Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. *Endocrinology* 140, 1005-1008
22. Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., and Simpson, E. R. (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. *N Engl J Med* 337, 91-95

## Referenzen

23. Reginster, J. Y., Deroisy, R., Fontaine, M. A., and Franchimont, P. (1992) Influence of estrogen replacement therapy on endogenous calcitonin production rates. *Gynecol Endocrinol* 6, 65-71
24. McKane, W. R., Khosla, S., Peterson, J. M., Egan, K., and Riggs, B. L. (1994) Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. *J Bone Miner Res* 9, 1313-1318
25. Reginster, J. Y. (1992) Calcitonin and bone diseases. *Lancet* 339, 1064-1065
26. Adebajo, O. A., Moonga, B. S., Yamate, T., Sun, L., Minkin, C., Abe, E., and Zaidi, M. (1998) Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca<sup>2+</sup> sensing in the regulation of osteoclastic bone resorption. *J Cell Biol* 142, 1347-1356
27. Gao, Y., Morita, I., Maruo, N., Kubota, T., Murota, S., and Aso, T. (1998) Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. *Bone* 22, 487-493
28. Schiller, C., Gruber, R., Redlich, K., Ho, G. M., Katzgraber, F., Willheim, M., Pietschmann, P., and Peterlik, M. (1997) 17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures. *Endocrinology* 138, 4567-4571
29. Devlin, R. D., Reddy, S. V., Savino, R., Ciliberto, G., and Roodman, G. D. (1998) IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. *J Bone Miner Res* 13, 393-399
30. Kurokouchi, K., Kambe, F., Yasukawa, K., Izumi, R., Ishiguro, N., Iwata, H., and Seo, H. (1998) TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. *J Bone Miner Res* 13, 1290-1299
31. Fernandez-Martin, J. L., Kurian, S., Farmer, P., and Nanes, M. S. (1998) Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors. *Mol Cell Endocrinol* 141, 65-72
32. Jimi, E., Nakamura, I., Duong, L. T., Ikebe, T., Takahashi, N., Rodan, G. A., and Suda, T. (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. *Exp Cell Res* 247, 84-93
33. Assuma, R., Oates, T., Cochran, D., Amar, S., and Graves, D. T. (1998) IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. *J Immunol* 160, 403-409
34. Evans, D. M., and Ralston, S. H. (1996) Nitric oxide and bone. *J Bone Miner Res* 11, 300-305
35. Garcia, C., Boyce, B. F., Gilles, J., Dallas, M., Qiao, M., Mundy, G. R., and Bonewald, L. F. (1996) Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. *J Bone Miner Res* 11, 1619-1627
36. Okada, Y., Pilbeam, C., Raisz, L., and Tanaka, Y. (2003) Role of cyclooxygenase-2 in bone resorption. *J Uoeh* 25, 185-195
37. Conference, C. D. (1993) In, Honkong
38. Ringe, J. D. (1996) *Osteoporose, Differenzialdiagnose und Differenzialtherapie*, Thieme Verlag, Stuttgart
39. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89, 309-319
40. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., and Higashio, K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. *Biochem Biophys Res Commun* 234, 137-142
41. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 139, 1329-1337
42. Kwon, B. S., Wang, S., Udagawa, N., Haridas, V., Lee, Z. H., Kim, K. K., Oh, K. O., Greene, J., Li, Y., Su, J., Gentz, R., Aggarwal, B. B., and Ni, J. (1998) TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. *Faseb J* 12, 845-854
43. Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E., and Clark, E. A. (1998) OPG/FDCR-1, a TNF receptor family

## Referenzen

- member, is expressed in lymphoid cells and is up-regulated by ligating CD40. *J Immunol* 161, 6113-6121
44. Tan, K. B., Harrop, J., Reddy, M., Young, P., Terrett, J., Emery, J., Moore, G., and Truneh, A. (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. *Gene* 204, 35-46
  45. Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., and Khosla, S. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology* 140, 4382-4389
  46. Viereck, V., Grundker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K. H., Raddatz, D., Emons, G., and Hofbauer, L. C. (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. *J Clin Endocrinol Metab* 88, 4206-4213
  47. Brandstrom, H., Jonsson, K. B., Vidal, O., Ljunghall, S., Ohlsson, C., and Ljunggren, O. (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. *Biochem Biophys Res Commun* 248, 454-457
  48. Viereck, V., Grundker, C., Blaschke, S., Siggelkow, H., Emons, G., and Hofbauer, L. C. (2002) Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. *J Cell Biochem* 84, 725-735
  49. Brandstrom, H., Bjorkman, T., and Ljunggren, O. (2001) Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. *Biochem Biophys Res Commun* 280, 831-835
  50. Makiishi-Shimobayashi, C., Tsujimura, T., Iwasaki, T., Yamada, N., Sugihara, A., Okamura, H., Hayashi, S., and Terada, N. (2001) Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. *Biochem Biophys Res Commun* 281, 361-366
  51. Wan, M., Shi, X., Feng, X., and Cao, X. (2001) Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression. *J Biol Chem* 276, 10119-10125
  52. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., and Osdoby, P. (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. *J Biol Chem* 276, 20659-20672
  53. Vidal, N. O., Brandstrom, H., Jonsson, K. B., and Ohlsson, C. (1998) Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. *J Endocrinol* 159, 191-195
  54. Hofbauer, L. C., Shui, C., Riggs, B. L., Dunstan, C. R., Spelsberg, T. C., O'Brien, T., and Khosla, S. (2001) Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. *Biochem Biophys Res Commun* 280, 334-339
  55. Onyia, J. E., Miles, R. R., Yang, X., Halladay, D. L., Hale, J., Glasebrook, A., McClure, D., Seno, G., Churgay, L., Chandrasekhar, S., and Martin, T. J. (2000) In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. *J Bone Miner Res* 15, 863-871
  56. Brandstrom, H., Jonsson, K. B., Ohlsson, C., Vidal, O., Ljunghall, S., and Ljunggren, O. (1998) Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. *Biochem Biophys Res Commun* 247, 338-341
  57. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A* 95, 3597-3602
  58. Lum, L., Wong, B. R., Josien, R., Becherer, J. D., Erdjument-Bromage, H., Schlondorff, J., Tempst, P., Choi, Y., and Blobel, C. P. (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. *J Biol Chem* 274, 13613-13618
  59. Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L., and Fremont, D. H. (2001) Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. *J Clin Invest* 108, 971-979
  60. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997) A homologue of the

## Referenzen

- TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* 390, 175-179
61. Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003) Osteoclast differentiation and activation. *Nature* 423, 337-342
  62. Aubin, J. E., and Bonnellye, E. (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. *Osteoporos Int* 11, 905-913
  63. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., and Simonet, W. S. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev* 12, 1260-1268
  64. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveirados-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 397, 315-323
  65. Brosch, S., Redlich, K., and Pietschmann, P. (2003) [Pathogenesis of osteoporosis in rheumatoid arthritis]. *Acta Med Austriaca* 30, 1-5
  66. Buttgereit, F., Loddenkemper, K., Spies, C., Naumann, L., Perka, C., and Tripmacher, R. (2003) Studies of the effects of selective cox-2 inhibition in bone cells.
  67. Claria, J. (2003) Cyclooxygenase-2 biology. *Curr Pharm Des* 9, 2177-2190
  68. Michaux, C., and Charlier, C. (2004) Structural approach for COX-2 inhibition. *Mini Rev Med Chem* 4, 603-615
  69. Mahajan, A., and Sharma, R. (2005) COX-2 selective nonsteroidal anti-inflammatory drugs: current status. *J Assoc Physicians India* 53, 200-204
  70. Reddy, B. S., and Rao, C. V. (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. *J Environ Pathol Toxicol Oncol* 21, 155-164
  71. Patrignani, P. (2000) Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. *Toxicol Lett* 112-113, 493-498
  72. Swamy, M. V., Cooma, I., Patlolla, J. M., Simi, B., Reddy, B. S., and Rao, C. V. (2004) Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. *Mol Cancer Ther* 3, 215-221
  73. Grösch, S., Tegeder, I., Niederberger, E., Bräutigam, L., and Geisslinger, G. (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. *FASEB J* 15, 2742-2744
  74. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 342, 1946-1952
  75. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M., and Chen, C. S. (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. *J Biol Chem* 275, 11397-11403
  76. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D. J. (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. *Circulation* 102, 840-845
  77. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zuber, A., Hawk, E., and Bertagnoli, M. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 352, 1071-1080
  78. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowitz, J. B., Verburg, K. M., and Geis, G. S. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA* 284, 1247-1255
  79. White, W. B., Strand, V., Roberts, R., and Whelton, A. (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. *Am J Ther* 11, 244-250
  80. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., Michel, B., Luscher, T. F., Noll, G., and Ruschitzka, F. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. *Circulation* 107, 405-409
  81. Arend, W. P., and Dayar, J. M. (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. *Arthritis Rheum* 38, 151-160

## Referenzen

82. Mino, T., Sugiyama, E., Taki, H., Kuroda, A., Yamashita, N., Maruyama, M., and Kobayashi, M. (1998) Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. *Arthritis Rheum* 41, 2004-2013
83. Kokubu, T., Matsui, N., Fujioka, H., Tsunoda, M., and Mizuno, K. (1999) Low intensity pulsed ultrasound exposure increases prostaglandin E2 production via the induction of cyclooxygenase-2 mRNA in mouse osteoblasts. *Biochem Biophys Res Commun* 256, 284-287
84. Gelb, M. H., Jain, M. K., and Berg, O. G. (1994) Inhibition of phospholipase A2. *Faseb J* 8, 916-924
85. Siggelkow, H., Rebenstorff, K., Kurre, W., Niedhart, C., Engel, I., Schulz, H., Atkinson, M. J., and Hufner, M. (1999) Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. *J Cell Biochem* 75, 22-35
86. Stein, G. S., and Lian, J. B. (1993) Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. *Endocr Rev* 14, 424-442
87. Robey, P. G., and Termine, J. D. (1985) Human bone cells in vitro. *Calcif Tissue Int* 37, 453-460
88. Gundle, R., and Beresford, J. N. (1995) The isolation and culture of cells from explants of human trabecular bone. *Calcif Tissue Int* 56 Suppl 1, S8-10
89. Jaiswal, N., Haynesworth, S. E., Caplan, A. I., and Bruder, S. P. (1997) Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. *J Cell Biochem* 64, 295-312
90. Aronow, M. A., Gerstenfeld, L. C., Owen, T. A., Tassinari, M. S., Stein, G. S., and Lian, J. B. (1990) Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. *J Cell Physiol* 143, 213-221
91. Schulz, A. (1995) "True bone" in vitro? *Virchows Arch* 426, 103-105
92. Billiau, A., Edy, V. G., Heremans, H., Van Damme, J., Desmyter, J., Georgiades, J. A., and De Somer, P. (1977) Human interferon: mass production in a newly established cell line, MG-63. *Antimicrob Agents Chemother* 12, 11-15
93. Heremans, H., Billiau, A., Cassiman, J. J., Mulier, J. C., and de Somer, P. (1978) In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. *Oncology* 35, 246-252
94. Langub, M. C., Reinhardt, T. A., Horst, R. L., Malluche, H. H., and Koszewski, N. J. (2000) Characterization of vitamin D receptor immunoreactivity in human bone cells. *Bone* 27, 383-387
95. Schuchmann, S., Wiontzek, M., Burmester, G. R., and Buttgereit, F. (2004) Modulation of intracellular calcium signaling and mitochondrial function in cultured osteoblastic cells by dexamethasone and celecoxib during mechanical stimulation. *Clin Exp Rheumatol* 22, 184-196
96. Clover, J., and Gowen, M. (1994) Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? *Bone* 15, 585-591
97. Luo, X. H., Liao, E. Y., Su, X., and Wu, X. P. (2004) Parathyroid hormone inhibits the expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) in osteoblast-like MG-63 cells. *J Bone Miner Metab* 22, 19-25
98. Lindl, T. (2000) *Zell- und Gewebekultur* Vol. 4. Auflage, Spektrum Akademischer Verlag
99. Mueckler, M. (1994) Facilitative glucose transporters. *Eur J Biochem* 219, 713-725
100. Joost, H. G., and Thorens, B. (2001) The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). *Mol Membr Biol* 18, 247-256
101. Brosius, F. C., 3rd, Liu, Y., Nguyen, N., Sun, D., Bartlett, J., and Schwaiger, M. (1997) Persistent myocardial ischemia increases GLUT1 glucose transporter expression in both ischemic and non-ischemic heart regions. *J Mol Cell Cardiol* 29, 1675-1685
102. Medina, R. A., Southworth, R., Fuller, W., and Garlick, P. B. (2002) Lactate-induced translocation of GLUT1 and GLUT4 is not mediated by the phosphatidylinositol-3-kinase pathway in the rat heart. *Basic Res Cardiol* 97, 168-176
103. Shetty, M., Ismail-Beigi, N., Loeb, J. N., and Ismail-Beigi, F. (1993) Induction of GLUT1 mRNA in response to inhibition of oxidative phosphorylation. *Am J Physiol* 265, C1224-1229
104. Wang, G. L., and Semenza, G. L. (1993) Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. *J Biol Chem* 268, 21513-21518

## Referenzen

105. Petersen, W., Varoga, D., Zantop, T., Hassenpflug, J., Mentlein, R., and Pufe, T. (2004) Cyclic strain influences the expression of the vascular endothelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1alpha) in tendon fibroblasts. *J Orthop Res* 22, 847-853
106. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J., and Jelkmann, W. (1999) Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. *Blood* 94, 1561-1567
107. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. *Embo J* 17, 5085-5094
108. Gaber, T., Dziurla, R., Tripmacher, R., Burmester, G. R., and Buttgereit, F. (2005) Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! *Ann Rheum Dis* 64, 971-980
109. Giatromanolaki, A., Sivridis, E., Maltezos, E., Athanassou, N., Papazoglou, D., Gatter, K. C., Harris, A. L., and Koukourakis, M. I. (2003) Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther* 5, R193-201
110. Cramer, T., Yamanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., Firestein, G. S., Gerber, H. P., Ferrara, N., and Johnson, R. S. (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. *Cell* 112, 645-657
111. Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., and Gurtner, G. C. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med* 10, 858-864
112. Takeda, N., Maemura, K., Imai, Y., Harada, T., Kawanami, D., Nojiri, T., Manabe, I., and Nagai, R. (2004) Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. *Circ Res* 95, 146-153
113. Koch, A. E. (2003) Angiogenesis as a target in rheumatoid arthritis. *Ann Rheum Dis* 62 Suppl 2, ii60-67
114. Löffler, G., and Petrides, P. E. (1998) *Biochemie und Pathobiochemie* Vol. 6. Auflage, Springer Verlag
115. Hamrahian, A. H., Zhang, J. Z., Elkhairi, F. S., Prasad, R., and Ismail-Beigi, F. (1999) Activation of Glut1 glucose transporter in response to inhibition of oxidative phosphorylation. *Arch Biochem Biophys* 368, 375-379
116. Krause, M. M., Brand, M. D., Krauss, S., Meisel, C., Vergin, H., Burmester, G. R., and Buttgereit, F. (2003) Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. *Arthritis Rheum* 48, 1438-1444
117. Romeis, B. (1989) *Alkalische Phosphatase* Vol. 17. Auflage, Urban&Schwarzenberg
118. Qiagen (06/2001) RNeasy Mini Handbook. In
119. Carter, M. J., and Milton, I. D. (1993) An inexpensive and simple method for DNA purifications on silica particles. *Nucleic Acids Res* 21, 1044
120. Vogelstein, B., and Gillespie, D. (1979) Preparative and analytical purification of DNA from agarose. *Proc Natl Acad Sci U S A* 76, 615-619
121. Biochemicals, R. M. (10/2000) Lightcycler Operator's Manual, Version 3.5.
122. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. (1995) Molekularbiologie der Zelle. *VCH*, 372-373
123. Morrison, T. B., Weis, J. J., and Wittwer, C. T. (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. *Biotechniques* 24, 954-958, 960, 962
124. Bustin, S. A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* 25, 169-193
125. Kreuzer, K. A., Lass, U., Landt, O., Nitsche, A., Laser, J., Ellerbrok, H., Pauli, G., Huhn, D., and Schmidt, C. A. (1999) Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. *Clin Chem* 45, 297-300
126. (1994) Molekulare und Medizinische Genetik. *Deutsches Ärzteblatt* 91, 1150-1169
127. Sanger, F., Nicklen, S., and Coulson, A. R. (1992) DNA sequencing with chain-terminating inhibitors. 1977. *Biotechnology* 24, 104-108
128. Immundiagnostik (03/2004) Osteoprotegerin ELISA. Zur Bestimmung des OPG aus Serum, Plasma, Urin und Zellkulturüberständen. Arbeitsanleitung. In
129. Tripmacher, R. (2005) Untersuchungen zu Wirkungen einer eingeschränkten Energiesynthese auf Funktionen humaner Immunzellen.

## Referenzen

130. Davies, N. M., McLachlan, A. J., Day, R. O., and Williams, K. M. (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. *Clin Pharmacokinet* 38, 225-242
131. Niederberger, E., Manderscheid, C., Grosch, S., Schmidt, H., Ehnert, C., and Geisslinger, G. (2004) Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. *Biochem Pharmacol* 68, 341-350
132. Johnson, A. J., Hsu, A. L., Lin, H. P., Song, X., and Chen, C. S. (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca<sup>2+</sup>-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. *Biochem J* 366, 831-837
133. Jendrossek, V., Handrick, R., and Belka, C. (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. *Faseb J* 17, 1547-1549
134. Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, H., Euchenhofer, C., Bräutigam, L., Grösch, S., and Geisslinger, G. (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. *FASEB J* 15, 1622-1624
135. Wang, J. L., Lin, K. L., Chen, J. S., Lu, Y. C., Jiann, B. P., Chang, H. T., Hsu, S. S., Chen, W. C., Huang, J. K., Ho, C. M., and Jan, C. R. (2004) Effect of celecoxib on Ca<sup>2+</sup> movement and cell proliferation in human osteoblasts. *Biochem Pharmacol* 67, 1123-1130
136. Fleming, I. (2001) Cytochrome p450 and vascular homeostasis. *Circ Res* 89, 753-762
137. Levitt, R. J., and Pollak, M. (2002) Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. *Cancer Res* 62, 7372-7376
138. Owen, T. A., Aronow, M., Shalhoub, V., Barone, L. M., Wilming, L., Tassinari, M. S., Kennedy, M. B., Pockwinse, S., Lian, J. B., and Stein, G. S. (1990) Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. *J Cell Physiol* 143, 420-430
139. Kasperk, C., Wergedal, J., Strong, D., Farley, J., Wangerin, K., Gropp, H., Ziegler, R., and Baylink, D. J. (1995) Human bone cell phenotypes differ depending on their skeletal site of origin. *J Clin Endocrinol Metab* 80, 2511-2517
140. Reddy, B. S., and Rao, C. V. (2000) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. *J Environ Pathol Toxicol Oncol* 21, 155-164
141. Song, X., Lin, H. P., Johnson, A. J., Tseng, P. H., Yang, Y. T., Kulp, S. K., and Chen, C. S. (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. *J Natl Cancer Inst* 94, 545-546
142. Goodman, S., Ma, T., Trindade, M., Ikenoue, T., Matsuura, I., Wong, N., Fox, N., Genovese, M., Regula, D., and Smith, R. L. (2002) COX-2 selective NSAID decreases bone ingrowth in vivo. *Orthop Res* 20, 1164-1169
143. Endo, K., Sairyo, K., Komatsubara, S., Sasa, T., and Egawa, H. (2002) Cyclooxygenase-2 inhibitor inhibits the fracture healing. *J Physiol Anthropol Appl Human Sci* 21, 235-238
144. Liu, X. H., Kirschenbaum, A., Yao, S., and Levine, A. C. (2004) Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor of nuclear factor- $\kappa$ B (RANK) ligand/RANK system. *Endocrinology* 146, 1991-1998
145. Choi, B. K., Moon, S. Y., Cha, J. H., Kim, K. W., and Yoo, Y. J. (2005) Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by *Porphyromonas gingivalis*, *Treponema denticola*, and *Treponema socranskii*. *J Periodontol* 76, 813-820
146. Wei, X., Zhang, X., Zuscik, M. J., Drissi, M. H., Schwarz, E. M., and O'Keefe, R. J. (2005) Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. *J Bone Miner Res* 20, 1136-1148
147. Emergy, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic Ligand TRAIL. *J Biol Chem* 273, 14363-14367
148. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 277, 818-821
149. Holen, I., Croucher, P. I., Hamdy, F. C., and Eaton, C. L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. *Breast Cancer Res Treat* 62, 1619-1623

## Referenzen

150. Neville-Webbe, H. L., Cross, N. A., Eaton, C. L., Nyambo, R., Evans, C. A., Coleman, R. E., and Holen, I. (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. *Breast Cancer Res Treat* 86, 269-279
151. Hu, F., Wang, X., Pace, T. W., Wu, H., and Miller, A. H. (2005) Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. *Mol Psychiatry* 10, 426-428
152. Gu, G., Hentunen, T. A., Nars, M., Harkonen, P. L., and Vaananen, H. K. (2005) Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. *Apoptosis* 10, 583-595
153. Mingatto, F. E., Santos, A. C., Uyemura, S. A., Jordani, M. C., and Curti, C. (1996) In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. *Arch Biochem Biophys* 334, 303-308
154. Caparroz-Assef, S. M., Salgueiro-Pagadigorria, C. L., Bersani-Amado, C. A., Bracht, A., Kelmer-Bracht, A. M., and Ishii-Iwamoto, E. L. (2001) The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant induced arthritic rats. *Cell Biochem Funct* 19, 117-124
155. Petrescu, I., and Tarba, C. (1997) Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. *Biochem Biophys Acta* 1318, 385-394
156. Moreno-Sanchez, R., Bravo, C., Vasquez, C., Ayala, G., Silveira, L. H., and Martinez-Lavin, M. (1999) Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells and whole heart. *Biochem Pharmacol* 57, 743-752
157. Jacob, M., Bjarnason, I., Rafi, S., Wrigglesworth, J., and Simpson, R. J. (2001) A study of the effects of indometacin on liver mitochondria from rats, mice and humans. *Aliment Pharmacol Ther* 15, 1837-1842
158. Mahmud, T., Rafi, S. S., Scott, D. L., Wrigglesworth, J. M., and Bjarnason, I. (1996) Nonsteroidal anti-inflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. *Arthritis Rheum* 39, 1998-2003
159. Tibble, J. A., Sighthorsson, G., Foster, R., and Bjarnason, I. (2000) Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. *Scand J Gastroenterol* 35, 802-807
160. Masubuchi, Y., Yamada, S., and Horie, T. (2000) Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. *J Pharmacol Exp Ther* 292, 982-987
161. Somasundaram, S., Rafi, S., Hayllar, J., Sigthorsson, G., Jacob, M., Price, A. B., Macpherson, A., Mahmud, T., Scott, D., Wrigglesworth, J. M., and Bjarnason, I. (1997) Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. *Gut* 41, 344-353
162. Tretter, L., Chinopoulos, C., and Adam-Vizi, V. (1998) Plasma membrane depolarization and disturbed Na<sup>+</sup> homeostasis induced by the protonophore carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazone in isolated nerve terminals. *Mol Pharmacol* 53, 734-741
163. Budd, S. L., and Nicholls, D. G. (1996) A reevaluation of the role of mitochondria in neuronal CA<sup>2+</sup> homeostasis. *J Neurochem* 66, 403-411
164. Becker, M., Newman, S., and Ismail-Beigi, F. (1996) Stimulation of GLUT1 glucose transporter expression in response to inhibition of oxidative phosphorylation: role of reduced sulfhydryl groups. *Mol Cell Endocrinol* 121, 165-170
165. Shi, Y., Liu, H., Vanderburg, G., Samuel, S. J., Ismail-Beigi, F., and Jung, C. Y. (1995) Modulation of GLUT1 intrinsic activity in Clone 9 cells by inhibition of oxidative phosphorylation. *J Biol Chem* 270, 21772-21778
166. Koike, H., Uzawa, K., Grzesik, W. J., Seki, N., Endo, Y., Kasamatsu, A., Yamauchi, M., and Tanzawa, H. (2005) GLUT1 is highly expressed in cementoblasts but not in osteoblasts. *Connect Tissue Res* 46, 1-8
167. Harvey, A. J., Kind, K. L., and Thompson, J. G. (2004) Effect of the oxidative phosphorylation uncoupler 2,4-dinitrophenol on hypoxia-inducible factor-regulated gene expression in bovine blastocysts. *Reprod Fertil Dev* 16, 665-673
168. Thomas, D. M., Rogers, S. D., Ng, K. W., and Best, J. D. (1996) Dexamethasone modulates insulin receptor expression and subcellular distribution of the glucose transporter GLUT1 in UMR 106-01, a clonal osteogenic sarcoma cell line. *J Mol Endocrinol* 17, 7-17
169. Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., and Thompson, C. B. (2002) The CD28 signaling pathway regulates glucose metabolism. *Immunity* 16, 769-777
170. Barata, J. T., Cardoso, A. A., and Boussiotis, V. A. (2005) Interleukin-7 in T-cell acute lymphoblastic leukaemia: an extrinsic factor supporting leukemogenesis. *Leuk Lymphoma* 46, 483-495



## Referenzen

171. Pelletier, A., Joly, E., Prentki, M., and Coderre, L. (2005) Adenosin 5'-monophosphate-activated protein kinase and p38 mitogen-activated protein kinase participate in the stimulation of glucose uptake by dinitrophenol in adult cardiomyocytes. *Endocrinology* 146, 2285-2294
172. Zhang, J. Z., Behrooz, A., and Ismail-Beigi, F. (1999) Regulation of glucose transport by hypoxia. *Am J Kidney Dis* 34, 189-202
173. Ebert, B. L., Firth, J. D., and Ratcliffe, P. J. (1995) Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. *J Biol Chem* 270, 29083-29089
174. Yu, A. Y., Frid, M. G., Shimoda, L. A., Wiener, C. M., Stenmark, K., and Semenza, G. L. (1998) Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. *Am J Physiol* 275, L818-826
175. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., and Neckers, L. (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. *FASEB J* 17, 2115-2117
176. Zhong, H., Willard, M., and Simons, J. (2004) NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. *Int J Cancer* 112, 585-595
177. Palayoor, S. T., Tofilon, P. J., and Coleman, C. N. (2003) Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. *Clin Cancer Res* 9, 3150-3157
178. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. (2002) Von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. *FASEB J* 16, 264-266
179. Ito, M., Tanaka, S., Kim, S., Kuwai, T., Matsutani, N., Kamada, T., Kitadai, Y., Sumii, M., Yoshihara, M., Haruma, K., and Chayama, K. (2003) The specific expression of hypoxia inducible factor-1alpha in human gastric mucosa induced by nonsteroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 18, 90-98